Tendering and biosimilars: what role for value-added services?
Authors:
Open Access
- 22 December 2019
- journal article
- review article
- Published by MDPI AG in Journal of Market Access & Health Policy
- Vol. 8 (1) , 1705120
Abstract
Background: Access to biologic medicines (including biosimilars) across Europe is largely governed by a process of tendering conducted by health authorities. Over-reliance on treatment costs in awarding tenders has the potential to hinder competition and undermine the long-term sustainability of biosimilars. Objective: To assess the extent and impact of consideration of 'value-added services' (VAS) in tendering for biosimilars, we conducted a narrative review of published literature. Results: Findings from survey-based publications indicated that tendering practices for biosimilars are widely used, with cost being the main determinant of success and little detail being available on other criteria where these apply. Criteria (of therapeutic and technical interest) beyond price were included in one tendering specification for infliximab (originator and biosimilars), while a separate tender for the same product included VAS in the form of therapeutic drug monitoring, measurement of antibodies and calprotectin. Conclusions: Published evidence concerning inclusion of VAS in tendering for biosimilars is lacking. Development and implementation of standardized criteria and methods of assessment for tenders may avoid manufacturers facing segmented markets, encourage competition and the longer-term sustainability of biosimilars, and realize the healthcare system and patient benefits these treatments can bring.Keywords
Funding Information
- Pfizer (not applicable)
This publication has 20 references indexed in Scilit:
- Drug tendering: drug supply and shortage implications for the uptake of biosimilarsClinicoEconomics and Outcomes Research, 2017
- A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registryAnnals of the Rheumatic Diseases, 2017
- Assessing the Value of Biosimilars: A Review of the Role of Budget Impact AnalysisPharmacoEconomics, 2017
- Pricing and Reimbursement of Biosimilars in Central and Eastern European CountriesFrontiers in Pharmacology, 2017
- Tendering for off-patent outpatient medicines: lessons learned from experiences in Belgium, Denmark and the NetherlandsJournal of Pharmaceutical Health Services Research, 2017
- Combining Therapeutic Drug Monitoring with Biosimilars, a Strategy to Improve the Efficacy of Biologicals for Treating Inflammatory Bowel Diseases at an Affordable CostDigestive Diseases, 2017
- Supply-side and demand-side policies for biosimilars: an overview in 10 European member statesJournal of Market Access & Health Policy, 2017
- Beyond the pill: The move towards value-added services in the pharmaceutical industryJournal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing, 2014
- Tendering for outpatient prescription pharmaceuticals: What can be learned from current practices in Europe?Health Policy, 2011
- The value of value-added services.2008